What Level 1 Clinical Affairs Maturity Looks Like in Medical Device Organizations

The regulatory affairs manager calls a meeting. EU MDR requires updated clinical evaluation reports for every device in the portfolio — not the three-page literature summaries that passed under MDD, but substantive analytical documents with defined search protocols, critical appraisal, and benefit-risk conclusions. Your clinical affairs function consists of one person who writes regulatory submissions. She's never written a CER that would satisfy MDCG 2020-13.

This meeting is where Level 1 becomes visible. Not as an abstraction on a maturity chart, but as a concrete organizational problem with regulatory deadlines attached to it.

What Level 1 Actually Looks Like Day to Day

There is no clinical affairs function. There is a person — sometimes a regulatory affairs specialist, sometimes a quality engineer, sometimes an external consultant hired three weeks before a submission deadline — who produces a document called a Clinical Evaluation Report. That document summarizes published literature about the device or devices claimed as equivalent. It does not critically appraise the evidence. It does not assess methodological quality of individual studies. It does not construct a benefit-risk argument from weighted evidence. It describes what was found in the literature and concludes that the device is safe and performs as intended.

Under MDD, this was often sufficient. Under EU MDR, it is not. The distinction matters because many organizations at Level 1 believe their CERs are adequate. They followed a template. They searched PubMed. They cited studies. The document exists. But when a notified body reviewer trained on MDCG 2020-13 expectations reads that document, she finds a literature summary where a clinical evaluation should be. The deficiency letter that follows does not ask for minor revisions. It asks for a fundamentally different document.

The literature search itself is the first failure point. At Level 1, searches are informal — a few terms entered into PubMed, results skimmed for relevance, selected papers cited in the CER. There is no documented search protocol. No predefined inclusion and exclusion criteria. No requirement for multiple databases. No PRISMA flow diagram. No archived search results that would allow a reviewer to reproduce the search and verify completeness. When the notified body asks for the literature search protocol and screening documentation, the organization cannot produce them because they do not exist.

Equivalence claims compound the problem. EU MDR Article 61(5) requires technical, biological, and clinical equivalence to be demonstrated — not asserted. For Class III and implantable devices, the regulation requires a contract with the equivalent device manufacturer ensuring access to technical documentation. Level 1 organizations claim equivalence to predicate devices based on shared intended purpose and general design similarity. They have no contract with the equivalent device manufacturer. They have no access to the technical file. Their equivalence demonstration would not survive the first question in a notified body review.

The PMCF Gap

Post-market clinical follow-up at Level 1 is a statement in the CER, not an activity. The PMCF Plan, if one exists, contains language about monitoring literature and collecting clinical feedback. It does not specify endpoints. It does not define methods. It does not calculate sample sizes. It does not establish timelines or evaluation criteria. No PMCF data has ever been collected because there is no PMCF program to collect it.

This means the periodic safety update report — required under EU MDR Article 86 — lacks the PMCF input that should form a core component. It means the clinical evaluation cannot be updated with post-market clinical data because none has been generated. It means the continuous clinical evaluation cycle that EU MDR envisions does not exist. The clinical evaluation was produced once, at the time of the initial submission, and it sits unchanged until someone asks about it.

The People Problem

At Level 1, nobody in the organization meets EU MDR clinical evaluator qualification requirements as interpreted by MDCG 2020-13. The person writing the CER may be competent in regulatory affairs, quality systems, or technical writing. She is not a clinical evaluator with sufficient clinical and scientific expertise in the relevant therapeutic area to critically appraise clinical data and construct an evidence-based benefit-risk argument.

This is not a documentation gap that can be solved by putting a CV on file. When the evaluator lacks domain expertise, the evaluation itself is shallow. Methodological limitations in published studies go unrecognized. Bias in study designs is not identified. The clinical significance of reported outcomes is not assessed. The benefit-risk analysis becomes a formality rather than the analytical core of the clinical evaluation.

Management does not see clinical affairs as a function requiring investment because it has never been one. There is no clinical affairs line in the budget. There are no clinical affairs metrics in management review. The connection between clinical evidence quality and market access speed — or market access at all — is not understood at the leadership level. Clinical evidence is a cost center that produces documents when asked.

The Signals Are Unmistakable

CERs produced in weeks rather than months. No clinical evaluation plans as standalone documents. Literature searches that cannot be reproduced. PMCF plans with no specific study designs. No one in the organization who can name the qualified clinical evaluators or produce their credentials. Clinical affairs budget at zero as a distinct line item.

If this describes your organization, the regulatory exposure is not theoretical. Notified bodies conducting detailed technical documentation reviews under EU MDR are returning deficiency letters that require fundamental rework — not of individual CERs, but of the entire clinical evaluation approach. FDA is raising clinical evidence expectations across device categories. The gap between what Level 1 produces and what regulators now require is widening, not narrowing.

The path forward starts with an honest assessment of where you stand. The MedTechCMM clinical affairs assessment evaluates each dimension of clinical evidence capability independently, identifies which gaps present the greatest regulatory risk, and maps them to specific remediation actions. Begin at /assessments/clinical-affairs.